Live
FierceBiotechHerantis taps Indivi for digital biomarker tech in Parkinson’s disease trialEndpoints NewsRelay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study10x Genomics NewsUnderstanding plate, droplet and microwell approaches in single-cell RNA sequencing - News-MedicalLonza NewsGlobal Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - Yahoo Finance SingaporeFierceBiotechRelay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorderEndpoints NewsBioMarin's rare disease therapy shows no clinical benefit in Phase 3 testClinical OMICsFDA-Approved Asthma Drug Boosts Efficacy of Immunotherapy in Aggressive Cancers10x Genomics Blog10X Genomics’ SWOT analysis: stock faces profitability test - Investing.comEdwards LifesciencesEdwards Lifesciences stock (US28176E1082): heart-valve specialist in focus after latest earnings upd - AD HOC NEWSCharles RiverCharles River Laboratories stock (US1591881009): Fresh earnings and outlook keep investors focused o - AD HOC NEWSLonza NewsLonza Group AG stock (CH0013841017): pharma supplier in focus after 2025 results and dividend decisi - AD HOC NEWSLabCorpLabcorp stock (US50540R4092): Q1 results, new contracts and healthcare demand in focus - AD HOC NEWS
Agilent Feb 11, 2026

Own Agilent stock by March 31? A $0.255 cash payout is coming in April - Stock Titan

Own Agilent stock by March 31? A $0.255 cash payout is coming in April - Stock Titan

Original
Body unavailable. Use the original source.